Simple 3-Marker Index May Flag CKM Syndrome Risk Before Costly Disease Progression

Why It Matters

The CHG index gives payers and health systems a simple, inexpensive metric to flag high‑risk individuals before expensive disease progression, enabling earlier, targeted interventions and more efficient population‑health management.

Key Takeaways

• CHG index links cholesterol, HDL, glucose to CKM syndrome risk.
• One SD rise raises diabetes risk by 47% in UK cohort.
• Elevated CHG predicts 12% higher MACCE risk in CAD patients.
• Tool uses only three routine lab tests, enabling low‑cost screening.

Pulse Analysis

The rise of cardiovascular‑kidney‑metabolic (CKM) syndrome as a unified clinical construct reflects growing recognition that metabolic dysfunction, chronic kidney disease and cardiovascular disease often progress together. Traditional risk models treat these components in isolation, leaving clinicians without a single, actionable metric that captures their combined burden. The cholesterol‑HDL‑glucose (CHG) index fills that gap by merging three universally measured laboratory values—total cholesterol, HDL‑C, and fasting glucose—into a composite score that mirrors the intertwined pathophysiology of insulin resistance, dyslipidemia, and endothelial stress.

In the recent analysis, investigators leveraged the massive UK Biobank cohort (nearly 371,000 participants) and a Chinese coronary artery disease registry (8,494 patients) to test the CHG index across the full CKM spectrum. Fine‑Gray and Cox models consistently linked each standard‑deviation increase in CHG to a 47% higher hazard of incident type 2 diabetes, modest but significant elevations in cardiovascular and kidney disease risk, and a 12% rise in major adverse cardiovascular and cerebrovascular events among high‑risk CAD patients. A causal‑forest algorithm further isolated a subgroup with low systemic inflammation yet high hemoglobin A1C where the prognostic signal intensified, underscoring the index’s ability to pinpoint nuanced risk phenotypes.

For health‑system leaders and insurers, the CHG index offers a pragmatic tool for population‑health management. Because the three inputs are already part of routine panels, integrating the index into electronic health records can automate risk stratification without additional testing costs. This enables proactive outreach, lifestyle coaching, or pharmacologic interventions for individuals poised to cross into costly CKM stages. While the study’s observational nature and predominance of European ancestry limit causal inference and generalizability, the replication across distinct cohorts bolsters confidence. Future work should explore prospective validation, integration with digital health platforms, and whether targeted interventions based on CHG scores can blunt the trajectory toward advanced CKM disease.